Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation  

作　　者：Qiwen Yang Xiaoling Ma Fupin Hu Jing Zhang Tongwen Sun Baiyi Chen Yingchun Xu Youning Liu Chinese Committee on Antimicrobial Susceptibility Testing(ChiCAST) Expert Committee on Infectious Diseases,China Medical Education Association 

机构地区：[1]Department of Clinical Laboratory,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China [2]Department of Laboratory Medicine,the First Affiliated Hospital,University of Science and Technology of China,Hefei 230001,China [3]lnstitute of Antibiotics,Huashan Hospital,Fudan University,Shanghai 200040,China [4]General ICU,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China [5]Department of Infectious Diseases,the First Affiliated Hospital,China Medical University,Shenyang 110001,China [6]Department of Respiratory Medicine,the First Medical Center of PLA General Hospital,Beijing 100853,China [7]不详

出　　处：《Chinese Medical Sciences Journal》2021年第1期1-16,共16页中国医学科学杂志（英文版）

基　　金：the National Key Research&Development Program(2018YFC1200100,2018YFC1200105);the Major Research and Development Project of Innovative Drugs,Ministry of Science and Technology of China(2017ZX09304005).

摘　　要：The polymyxins are important antimicrobial agents against antibiotic-resistant gram-negative bacilli.In 2020,the Clinical and Laboratory Standards Institute modified the clinical breakpoints for polymyxin susceptibility test by eliminating the"susceptible"interpretive category,only reporting intermediate(≤2 mg/L)and resistant(≥4 mg/L).However,the European Committee on Antimicrobial Susceptibility Testing recommended the use of clinical breakpoints of W2 mg/L as susceptible and>2 mg/L as resistant.The first-line laboratorians and clinicians in China have been perplexed by the inconsistence of international polymyxin clinical breakpoints and discouraged by the difficulty of conducting polymyxin susceptibility testing.Therefore,it is urgently needed to make it clear for the laboratorians in China to know how to accurately carry out polymyxin susceptibility testing and standardize the interpretation of susceptibility testing results.To this end,the experts from relevant fields were convened to formulate this consensus statement on the testing and clinical interpretation of polymyxin susceptibility.Relevant recommendations are proposed accordingly for laboratorians and clinicians to streamline their daily work.

关 键 词：POLYMYXIN antimicrobial susceptibility testing clinical interpretation expert consensus 

分 类 号：R96[医药卫生—药理学]